Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877642 | 0.74 | BCHE (0.57) | ADORA2AADORA1BCHEHRH4HRH3 | |
| SCHEMBL605488 | 0.74 | HRH4 (0.64) | HRH4HRH3HRH2HRH1 | |
| SCHEMBL4872472 | 0.73 | KDM4E (0.44) | ADORA2AADORA1BCHEHRH4HRH3 | |
| SCHEMBL3341967 | 0.71 | BCHE (0.59) | ADORA2AADORA1BCHEHRH4HRH3 | |
| SCHEMBL4875280 | 0.69 | HPGD (0.39) | ADORA2AADORA1MAPK14BCHEHRH4 | |
| SCHEMBL4874208 | 0.69 | NPY5R (0.43) | ADORA2AADORA1MAPK14BCHEHRH4 | |
| SCHEMBL4877494 | 0.69 | MAPK14 (0.39) | ADORA2AADORA1MAPK14BCHEHRH4 | |
| SCHEMBL3493955 | 0.67 | MAOA (0.41) | BCHEKDM4EALDH1A1POLB | |
| SCHEMBL10196632 | 0.62 | — | — | |
| SCHEMBL4875017 | 0.60 | HRH4 (0.39) | ADORA2AADORA1BCHEHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | ADORA2A 1517/4885ADORA1 2541/4885MAPK14 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.